Schonfeld Strategic Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-13,700
Closed -$577K 2862
2022
Q3
$577K Hold
13,700
﹤0.01% 1653
2022
Q2
$1.96M Buy
+13,700
New +$1.96M 0.02% 751
2021
Q4
Sell
-100,000
Closed -$38.5M 2395
2021
Q3
$38.5M Buy
+100,000
New +$36.9M 0.4% 44

Other funds holding MRNA

Schonfeld Strategic Advisors's MRNA Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Moderna (MRNA) stake by 28% in Q1 2026, selling an estimated $284K and leaving 15,691 shares worth $797K. The position accounts for 0.01% of the portfolio, ranked #1199.

Schonfeld Strategic Advisors first reported a position in MRNA in Q1 2020 and has held it in 19 quarters since. The position peaked at $16.5M in Q2 2024. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Schonfeld Strategic Advisors held 15,691 shares of Moderna worth $797K as of Q1 2026.
  • Schonfeld Strategic Advisors sold 6,086 Moderna shares in Q1 2026, an estimated $284K.
  • Moderna made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1199 holding.
  • Schonfeld Strategic Advisors first reported a position in Moderna in Q1 2020 and has held it in 19 quarters since.
  • Schonfeld Strategic Advisors's Moderna position peaked at $16.5M in Q2 2024.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.